Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades

被引:69
作者
Bocca, ML
Le Doze, F
Etard, O
Pottier, M
L'Hoste, J
Denise, P
机构
[1] CHU, Fac Med, Physiol Lab, F-14032 Caen, France
[2] CHU, Fac Med, Pharmacol Lab, F-14032 Caen, France
[3] INRETS, Lab Psychol Conduite, F-94114 Arcueil, France
关键词
zolpidem; zopiclone; flunitrazepam; driving performance; residual effect; saccadic eye movement;
D O I
10.1007/s002130050961
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Studies report contradictory results concerning the residual effects of zolpidem and zopiclone. Moreover, residual effects of these compounds on healthy subjects have not yet been simultaneously assessed. Objective: The present study with healthy subjects investigated the residual effects of zolpidem 10 mg and zopiclone 7.5 mg on driving performance and on ocular saccade and compared them to those under flunitrazepam 1 mg and placebo. Methods: The study involved 16 subjects divided into two groups, a 9:00 a.m. group and a 11:00 a.m. group, in a balanced, double-blind, cross-over design. Results: In the 9:00 a.m. group, zolpidem had no residual effects while zopiclone and flunitrazepam both impaired driving performance (P < 0.001 for both) and increased saccadic latency (P < 0.005; P = 0.052, respectively). Zopiclone impaired driving performance 5 times less than did flunitrazepam. In the 11:00 a.m. group, zolpidem and zopiclone had no residual effects, while flunitrazepam increased saccadic latency (P = 0.065) but did not impair driving performance. Conclusions: Zopiclone and flunitrazepam had residual effects in the first part of the morning, whereas zolpidem had no residual effects. The hierarchical character of the effects of the molecules differed according to the test administered. This is probably linked more to drug-induced specific alterations than to different sensitivities of the tests.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 42 条
[1]   DIFFERENCE IN ACTION BETWEEN ORAL TRIAZOLAM AND ZOPICLONE [J].
AANTAA, R ;
SALONEN, M ;
NYRKE, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (01) :47-51
[2]  
BAHILL A T, 1975, Mathematical Biosciences, V24, P191, DOI 10.1016/0025-5564(75)90075-9
[3]   CALCULATION OF STRUCTURAL AND DEFECT PROPERTIES OF ALPHA-U3O8 [J].
BALL, RGJ ;
DICKENS, PG .
JOURNAL OF MATERIALS CHEMISTRY, 1991, 1 (01) :105-112
[4]   DAYTIME WAKEFULNESS FOLLOWING A BEDTIME ORAL DOSE OF ZOLPIDEM 20 MG, FLUNITRAZEPAM 2 MG AND PLACEBO [J].
BENSIMON, G ;
FORET, J ;
WAROT, D ;
LACOMBLEZ, L ;
THIERCELIN, JF ;
SIMON, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (03) :463-469
[5]   THE RELATIONSHIP BETWEEN PEAK VELOCITY OF SACCADIC EYE-MOVEMENTS AND SERUM BENZODIAZEPINE CONCENTRATION [J].
BITTENCOURT, PRM ;
WADE, P ;
SMITH, AT ;
RICHENS, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (04) :523-533
[6]   REPEATED DOSE EFFECTS OF LORMETAZEPAM AND FLURAZEPAM UPON DRIVING PERFORMANCE [J].
BROOKHUIS, KA ;
VOLKERTS, ER ;
OHANLON, JF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :83-87
[7]   BENZODIAZEPINE RECEPTOR-BINDING OF NONBENZODIAZEPINES INVIVO - ALPIDEM, ZOLPIDEM AND ZOPICLONE [J].
BYRNES, JJ ;
GREENBLATT, DJ ;
MILLER, LG .
BRAIN RESEARCH BULLETIN, 1992, 29 (06) :905-908
[8]  
CLODORE M, 1990, INSOMNIE IMIDAZOPYRI, V7, P95
[9]  
DOBLE A, 1992, ADV BIOCHEM PSYCHOPH, V47, P407
[10]  
ETARD O, 1993, VIGILANCE TRANSPORTS, P163